Quanterix Corp
$ 4.03
5.22%
07 Aug - close price
- Market Cap 189,837,000 USD
- Current Price $ 4.03
- High / Low $ 4.04 / 3.88
- Stock P/E N/A
- Book Value 6.00
- EPS -2.35
- Next Earning Report 2026-08-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.13 %
- ROE -0.35 %
- 52 Week High 8.77
- 52 Week Low 2.40
About
Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advance precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the regions from Asia Pacific. The company is headquartered in Billerica, Massachusetts.
Analyst Target Price
$4.33
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-03-02 | 2025-11-10 | 2025-08-07 | 2025-05-12 | 2025-03-17 | 2024-11-11 | 2024-08-08 | 2024-05-07 | 2024-02-29 | 2023-11-06 | 2023-08-07 |
| Reported EPS | 0.16 | -0.47 | -0.73 | -0.47 | -0.53 | -0.3 | -0.22 | -0.25 | -0.26 | -0.33 | -0.21 | -0.13 |
| Estimated EPS | -0.62 | -0.4322 | -0.53 | -0.41 | -0.43 | -0.254 | -0.23 | -0.26 | -0.31 | -0.32 | -0.4 | -0.41 |
| Surprise | 0.78 | -0.0378 | -0.2 | -0.06 | -0.1 | -0.046 | 0.01 | 0.01 | 0.05 | -0.01 | 0.19 | 0.28 |
| Surprise Percentage | 125.8065% | -8.746% | -37.7358% | -14.6341% | -23.2558% | -18.1102% | 4.3478% | 3.8462% | 16.129% | -3.125% | 47.5% | 68.2927% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-10 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: QTRX
2026-08-07 19:10:46
This article provides an update on Quanterix Corp (QTRX) stock, noting a recent price increase of 5.22% to $4.030. It indicates that more news regarding earnings, analyst ratings, and key developments will be available soon. The page serves as a hub for financial information on QTRX.
2026-08-07 19:10:46
This article provides an earnings forecast for Quanterix Corp (QTRX), detailing its current earnings forecast score, average price target, and analyst ratings. Based on 3 analysts, the stock has a "Hold" rating with an average price target of $6.50, suggesting a potential upside of 16.80%. The article also includes expected revenue and EPS for upcoming quarters.
2026-08-07 13:22:00
Quanterix Corp (QTRX) is set to release its Q2 2026 earnings on August 10, 2026, with revenue estimated at $37.46 million and an expected loss of $0.40 per share. While full-year 2026 revenue estimates have slightly declined, earnings estimates for 2027 have also seen a decrease. Analysts have an average "Hold" recommendation for QTRX with a 12-month target price of $4.33, while GuruFocus estimates a significant upside of 253.46% based on its GF Value of $13.52.
2026-08-06 14:42:40
First Eagle Investment Management, LLC has reported a beneficial ownership of 2,753,165 shares, or 5.8% of Quanterix Corp (QTRX) common stock, as of June 30, 2026. These shares grant First Eagle sole voting and dispositive power. The First Eagle Small Cap Opportunity Fund, advised by First Eagle, accounts for 2,421,533 of these shares, representing 5.1% of Quanterix's common stock.
2026-08-06 11:42:40
Quanterix Corporation (NASDAQ: QTRX) announced that its senior management will participate in the Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12, 2026. CEO Everett Cunningham will provide a company update during a live webcast fireside chat on August 12, and CTO Michael Miller will join a panel discussion on Neurology Diagnostics. The company will also hold one-on-one investor meetings at the event.
2026-08-06 06:00:00
Quanterix Corporation announced that its senior management will participate in the Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12, 2026. CEO Everett Cunningham will present in a fireside chat, and Chief Technology and Product Officer Michael Miller will join a panel on Neurology Diagnostics. The management team, including CFO Jason Faessler, will also hold one-on-one investor meetings during the event.
